anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To enable a user to take walking exercise for health care more rationally and efficiently by grasping the user&#39;s corpulence condition, while attaching a body fat measuring device to a pedometer, and indicating the necessary number of steps taken per day according t the level of the corpulence. SOLUTION: This health care device 1 for controlling the number of steps has four-terminal electrode comprising feeding side electrodes E1 and E1 and detecting side electrodes E2 and E2, which are electrically insulated from each other, disposed on the front and rear surfaces at right and left ends of a case C. The case C is connected to an attaching part T to be attached to the hip of a user in such a way that it can be opened/closed. An LCD display part D, measurement key K1, a figure up key K2, a figure down key K3 and a switch key K4 are arranged on the open/close inner front surface of the case C. The measurement key K1 is to start the measurement of the pedometer or the body fat measuring device. The figure up key K2 is to raise the figure by one point and input the figure by one press of the key.  The figure down key K3 is to lower the figure by one point and input the figure by one press of the key. The switch key K4 is to switch the pedometer and the body fat measuring device or to switch the menu including data input, target setting, etc.
The unit (1) to exfoliate a skin for removing dead cells, comprises a first external side (3) formed by an abrasive element (40), a second external side (4) formed by an alveolar element (60), an intermediate element coupled with abrasive and alveolar elements, and cleansing, exfoliating or peeling products. The alveolar element is different from the abrasive element, which has an abrasive capacity of 0.01-0.02 g/cm2&gt;/min. The abrasive element comprises foam with closed cells, which has an opening on an external side through an emerging side. The unit (1) to exfoliate a skin for removing dead cells, comprises a first external side (3) formed by an abrasive element (40), a second external side (4) formed by an alveolar element (60), an intermediate element with abrasive and alveolar elements are coupled, and cleansing, exfoliating or peeling products. The alveolar element is different from the abrasive element, which has an abrasive capacity of 0.01-0.02 g/cm2&gt;/min. The abrasive element comprises foam with closed cells, which has an opening on an external side through an emerging side. The foam is made up of polyethylene/polypropylene. The abrasive element has a thickness of 4-50 mm. The abrasive/alveolar element comprises a bactericidal/antifungal agent, an elastically deformable material, and opening passages of which one on the first external side and other in an interior of a body in which the elements are covered with a flocking. The alveolar element is made up of a polyurethane foam, which has an open/half-open cells to absorb cosmetic product, and a sintered plastic or mineral material. The alveolar element has an abrasive capacity, which is lower and higher than the abrasive element. The first external side is parallel to the second external side. The intermediate element has hardness higher than the alveolar element. The intermediate element isolates a side of the abrasive element, which is coupled with the intermediate element from a side of the alveolar element. The intermediate element is formed by a container for a cosmetic product. The container comprises body with an opening and a closing unit to close/restrict the opening of the body. The abrasive and the alveolar elements are retained on the external surface of the body and/or the closing unit. The abrasive element is located on an upper wall of the closing unit and the alveolar element is located on a sidewall of the body. The intermediate element forms a layer so that the abrasive and the alveolar elements are disposed on both sides of the layer. The abrasive element is coupled with the alveolar element by direct coupling, which is obtained by joining/welding.
PURPOSE:To inexpensively prepare the subject peptide by adjusting the pH of a milk raw material containing kappa-casein glycomacropeptide to a specific value and subsequently subjecting the treated raw material to an ultrafiltration treatment and a concentration treatment with an ultrafiltration membrane having a prescribed fractionation mol.wt. CONSTITUTION:A milk raw material (e.g. cheese whey or whey protein concentrate) containing kappa-casein glycomacropeptide is dissolved in water and adjusted to a pH of &lt;4 with hydrochloric acid, etc. The adjusted solution is subjected to an ultrafiltration treatment using an ultrafiltration membrane having a fractionation mol.wt. of 10000-50000 to give a penetration solution. The penetration solution is concentrated with an ultrafiltration membrane having a fractionation mol.wt. of &lt;=50000 to give the kappa-casein glycomacropeptide. The kappa-casein glycomacropeptide useful as a food raw material for preventing obesity, an infection preventing agent against influenza virus, etc., can be thereby prepared readily in a large amount in a high purity.
A polymeric substance which contains acid amide groups in which the amide nitrogen atom carries an amino aryl substituent may be produced by reacting an aromatic diamine containing one or two primary or secondary amine groups with a polymer containing acid halide functions of the formula COX in which X denotes a halogen, the reaction being effected in the presence of an agent assisting the elimination of the hydrogen halide.  The characteristic grouping of the polymers of this invention is &lt;FORM:0993181/C3/1&gt; where R is a substituted or non-substituted arylene group, R1 and R11 being a hydrogen atom or a substituted or non-substituted alkyl group. Preferred polymers are those having the characteristic structure &lt;FORM:0993181/C3/2&gt; where R111 is a hydrogen atom or a methyl grouping. Preferably at least 10% of the acid amide groups are substituted as indicated and up to 100% may be so substituted.  The preferred starting material is polyacrylyl chloride and suitable aromatic diamines are nitro-paraphenylene diamine, 1-methyl-amino-2-nitro-4-amino benzene, 1-methyl-amino-2-nitro-4-(b -diethylaminoethyl - amino)benzene, 1 - nitro - 3 - amino - 4 - (b  - diethylaminoethyl - amino) - benzene and 1-4-diaminoanthraquinone. Solutions of the polymeric material are used as hair-colouring compositions.  The compositions may additionally contain other water-soluble polymers such as polyvinyl pyrrolidine or a vinyl acetate-crotonic acid copolymer.ALSO:Solutions of a polymeric substance which contains acid amide groups in which the amide nitrogen atom carries an amino aryl substituent are used as low colouring compositions.  The polymers are formed by reacting an aromatic diamine containing one or two primary or secondary amine groups with a polymer containing acid halide functions.  The characteristic grouping of the polymers of this invention is &lt;FORM:0993181/D1-D2/1&gt; where R1, R11 and R111 are hydrogen or lower allyl and R is a substituted or unsubstituted arylene group.  The hair-colouring compositions may consist simply of solutions of the coloured polymeric materials or may contain additionally other polymers such as polyvinylpyrolidine or a crotonic acid-vinyl acetate copolymer.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sustained release fine particle preparation which uses granulated particles having a high bulk density and inhibiting adhesion and coagulation and has stable solubility, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The sustained release fine particle preparation is characterized in that theophylline-containing granulated particles prepared by spray-drying a dispersion comprising theophylline, a water-insoluble polymer such as a cellulose derivative or a (meth)acrylate-based polymer, and an aqueous solvent comprising water and a water-soluble organic solvent are coated with the water-insoluble polymer such as the cellulose derivative or the (meth)acrylate-based polymer. The sustained release fine particle preparation does substantially not contain a higher fatty acid glycerol ester. The ratio of the water to the water-soluble organic solvent may be about 100 pts. wt. to about 0.1 to 60 pts. wt.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide livestock and pet supplements for decreasing the weight of too fat animals and ameliorating physical constitution, to provide livestock feed mixed with the livestock supplements and to provide pet feed mixed with the pet supplements.  &lt;P&gt;SOLUTION: (1) The livestock supplements are obtained by adding biotin to tea leaf powder. (2) The pet supplements are obtained by adding biotin to tea leaf powder. (3) The supplement-containing livestock feed is obtained by mixing the supplements which are obtained by adding biotin to tea leaf powder with livestock feed. (4) The supplement-containing pet feed is obtained by mixing the supplements which are obtained by adding biotin to tea leaf powder with pet feed.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention provides canine heavy chain and light chain (both .lambda. and .kappa.) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presen t disclosed canine variable domain framework sequences and CDRs specific for a n antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninizati on permits the development of useful therapeutics, which includes but is not limited to allergy, osteoarcomma&#39;s and lymphomma&#39;s.
A facility stores a person&#39;s personal information (“PI”) on a portable storage device (“PSD”) of the person. In some cases, the PSD bears a fax number mapping uniquely to the person; when a fax containing the person&#39;s PI is sent to this fax number, the facility stores an encrypted version of the PI on a relay server (“RS”). When the PSD connects with an access device, the encrypted version of the PI is retrieved from the RS and stored on the PSD. In some cases, the PSD bears a non-textual visual symbol; when its images is captured by a device such as a smartphone, an identifier encoded in the symbol is used to transmit encrypted PI to the RS. In some cases, each access device reports aggregates of personal data to an analysis server. In some cases, the facility statistically obfuscates these aggregates for transmission to/storage on the analysis server.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to urology, and can be used for prolonging recurrence-free period of interstitial cystitis. Preliminary preparation of autologous plasma enriched with thrombocytes is performed, and its activation by means of 10 % solution of CaCl, puncturing of bladder walls. Plasma prepared from 100 ml of whole blood is prepared with triple increase of thrombocyte concentration. Freezing at temperature t -80 °C with subsequent defrosting on water bath t +40 °C. After activating with 10 % CaClsolution at ratio of 1:10, respectively, electric coagulation of the zone of ulcerous involvement of the bladder wall is performed, and immediately after that, the area is punctured every 2.0–3.0 mm, depth 2.0–3.0 mm, 1 prick – 1 ml, with the condition of introducing plasma and along the healthy edges of crater at 2–3 mm from its edge. Every 14 days, injections are repeated 4 times in the same mode. That is followed by 1, 3, 6, 12 months of clinical follow-up of the disease and a pinch biopsy of the zone of the urinary bladder wall ulcer with histologic and immunohistochemical examinations to evaluate the therapeutic results.EFFECT: method enables reducing pain syndrome, reducing frequency of urination, increasing reservoir capacity of urinary bladder, reducing frequency of recurrences, reduce the length of treatment, expand the scope of application by using autologous plasma enriched with thrombocytes, in interstitial cystitis with Hunner&#39;s involvement.1 cl, 2 dwg, 2 ex
A system is provided in which portable electronic devices may be provided to people for accessing services in mass quantities. Each portable electronic device, which may be a tablet, may be configured in advance with one or more service programs and an authentication process. The tablet may also include cellular data access and/or paired peripheral devices. Such pre-configuration may provide subsequent ease of use and/or guarantee compatibility with a provider&#39;s server. A device control module on the tablet may communicate with a device manager on a server to monitor progress of the service program. If data values associated with the service program, such as measurements and/or transferred content, fail to meet a threshold within a period of time, the device control module may implement an action on the device to encourage the user, such as triggering repetitive alerts, disabling cellular access, disabling system applications, and the like.
PCT No. PCT/SU89/00272 Sec. 371 Date Nov. 12, 1991 Sec. 102(e) Date Nov. 12, 1991 PCT Filed Jan. 12, 1989 PCT Pub. No. WO90/08135 PCT Pub. Date Jul. 26, 1990.A novel compound-ethyl 6-bromo-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethylind ole-3- carboxylate hydrochloride monohydrate having the following formula:   &lt;IMAGE&gt;   A process for preparing the compound according to the invention, characterized in that it comprises treating ethyl 5-acetoxy-1,2-dimethylindole-3-carboxylate with a brominating agent in an inert organic solvent under reflux, reacting the resultant ethyl 5-acetoxy-6-bromo-2-bromomethyl-1-methylindole-3-carboxylate with thiophenol in the presence of an alkali metal hydroxide or its alcoholate in an organic solvent, reacting the resultant ethyl 6-bromo-5-hydroxy-1-methyl-2-phenylthiomethylindole-3-carboxylate with an aminomethylating agent in an organic solvent at a temperature of from 65 DEG  C. to a temperature of refluxing the reaction mixture. The end product is then isolated from the resultant base-ethyl 6-bromo-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethylind ole-3- carboxylate. The compound according to the invention is an active principle of a pharmaceutical preparation having the antiviral, interferon-inducing and immunomodulatory effects.
The invention comprises steroids having in the A and B rings the structure &lt;FORM:1005639/C2/1&gt; (wherein R is alkoxy or hydroxyalkoxy and R1 is hydrogen or methyl) and their preparation by treating the corresponding 2-unsubstituted steroids with the Vilsmeier reagent followed by hydrolysis or by treating a corresponding 3,3-dialkoxy-5a -steroid saturated in ring A with not less than 2 molar equivalents of the Vilsmeier reagent followed by hydrolysis.  The reagent is prepared from formylated secondary amines and acid halides such as phosphorus halides, phosgene, thionyl chloride and oxalyl chloride. The starting materials may contain protected hydroxyl group (which may subsequently be regenerated), thiol, carbonyl, carbalkoxy, cyano, alkyl, alkenyl and alkylidene groups, lactone, ether and spiroketal residues, halogen atoms, unsaturated linkages, acylated ketol groups at most positions of the steroid nucleus and 17-side chain and a protected corticoid side chain. 16b  - Methyl - 16a ,17a  - epoxypregnen - 20 - ones are converted into the 2-formyl derivatives of 17a  - hydroxy - 16 - methylenepregnan - 20 - ones by using extra mole proportions of the reagent and 16a ,17a -epoxypregnan-20-ones are converted into 16b -halo-17a -hydroxypregnan-20-ones. Products containing a 3-formoxyalkoxy group may subsequently be hydrolysed to the required 3-hydroxyalkoxy compounds.  The preparation of a number of 2-formyl steroids of the androstane and pregnane series containing the above-mentioned groups and of the 2-for-myl-3-enol ethers of 5a -dihydrotestololactone is described and exemplified. The conversion of the products into 2-methyl-steroids; 2,3-pyrazolo-steroids and 2,3-oxazolo-steroids is also referred to.  Steroids having in the A and B rings the structure &lt;FORM:1005639/C2/2&gt; are prepared from the corresponding 3-ketones and the appropriate alkanols.  Steroids having in the A and B rings the structure &lt;FORM:1005639/C2/3&gt; are prepared either by pyrolysis of steroids of the structure VI or by catalytic hydrogenation of the corresponding 3-R-3,5-dienes; or they may be prepared in situ by treatment of steroids of the formula VI with one molar equivalent of the Vilsmeier reagent; or, when R is hydroxyalkoxy, they may also be prepared in situ by treatment of ring A saturated steroids having a 3-alkylenedioxy group with one molar equivalent of the Vilsmeier reagent.  17b -Acetoxy - 3,3 - dimethoxy - 17a  - methyl - 5a  - androstane; 17b  - acetoxy - 19 - nor - 5a  - androstan - 3 - one; 17b  - acetoxy - 17a  - methyl - 19-nor - 5a  - androstan - 3 - one; and 17b  - acetoxy - 6a ,17a  - dimethyl - 5a  - androstan - 3 - one are all prepared from the corresponding 17b -ols and acetic anhydride in pyridine.  Specification 1,005,640 is referred to.
The invention discloses a Huolong Dan, and belongs to the field of a high fever therapy of the traditional Chinese medical science. The Huolong Dan produces curative effects without causing a fever. The Huolong Dan is suitable for prevention and treatment on the Yang failure disease defined by the traditional Chinese medical science. The Huolong Dan has good effects of treating Yang failure and immunity decline caused by tumors, hepatitis B and leukemia. The Huolong Dan is widely suitable for prevention and treatment on multidisciplinary diseases such as stomach cold, lung cold-caused diseases, hand and foot cold, body cold, diuresis and deafness, and is a product for improving Yang qi and immunity. The Huolong Dan accords with a traditional Chinese medical science principle of diagnosis and treatment based on an overall analysis of the illness and the patient&#39;s condition, has a unique formula, obvious curative effects and strong and wide applicability, and is suitable for processing production.
&#34;NEW SYNTHESIS PROCEDURE OF A FAMILY OF PEPTIDES WITH OPIAC PROPERTIES&#34;, of general formula **(See formula)** Wherein R1 represents: a hydrogen atom, a carbobenzoxyl radical, a tert-butoxycarbonyl radical, a benzyl radical and the hydrocarbon skeleton of an amino acid; all of them linked to the α-amino group of the Tyr. R2 represents: a hydrogen atom, a carbobenzoxyl radical, and a benzyl radical and a linear or branched alkyl radical of 1 to 6 carbon atoms; all of them attached to the oxygen atom of the phenolic group of tyrosine. R3 represents: a saturated or unsaturated, linear or branched alkyl chain of 1 to 16 carbon atoms, when n is equal to a substitution, and may be located in the ortho, meta or para position with respect to the alanyl residue of the peptide chain, atoms of hydrogen for n = 5 substitutions and halogen atoms at different positions. R4 represents: a hydrogen atom, linear or branched aliphatic alkyl radicals attached to the oxygen atom of the α-carboxylic group of leucine, where R4 can contain from 1 to 6 carbon atoms, and esters of succinimide, characterized in that In a first step, an aqueous solution of L-leucine and Na H CO3 (mol to mol) is reacted with a solution of the N-carbobenzoxy-L-phenylalanine N-hydroxysuccinimide ester in dioxane (L-leucine molar ratio- ester 2: 1) one night. It is then acidified and the solvent is removed in vacuo. (Machine-translation by Google Translate, not legally binding)
The present disclosure provides a composition and method for whitening and restoring natural tooth color, and a composition for application to a skin cell, or a portion of an area of skin. Tooth whitening is a common procedure in general dentistry. It has become desirable for a person&#39;s teeth to appear white. Teeth can become stained by food and drink products, including tobacco, vegetables, coffee, tea, and wine. Teeth can also become stained by certain medications. Whitening agents can help remove stains on teeth. Flavorings may be used to add scent, flavor, and color to whitening agents to make the whitening compositions more desirable. A composition of the current disclosure may be applied to a skin cell, or a portion of an area of skin. The composition may decrease the appearance of wrinkles, fine lines, scars, and make a portion of skin appear to be more radiant. A composition of the current disclosure may be used on a skin condition, wherein the skin condition can be cause by a bacterium, a virus, an allergic reaction, or a weakened immune system.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a dental embedding material improved in its compressive strength after calination in a suitable range, while keeping characteristics specific to a gypsum-based embedding material.  &lt;P&gt;SOLUTION: This dental embedding material is obtained by adding an auxiliary material for increasing the compressive strength after calcination to a main material consisting mainly of a gypsum component and a silica component. At least one kind of compound selected from the group consisting of an alkali metal chloride, an alkaline earth metal chloride, and an alkaline earth metal fluoride is used as the auxiliary material, and added to the main material in amount of 0.01-0.3 pts.wt. based on 100 pts.wt. of the main material. When sodium chloride is used as the auxiliary material, the sodium chloride is added to the main material in an amount of 0.02-0.2 pts.wt. based on 100 pts.wt. of the main material. When calcium chloride is used as the auxiliary material, the calcium chloride is added to the main material in an amount of 0.03-0.1 pts.wt. based on 100 pts.wt. of the main material.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula:wherein R1 is selected from the group consisting of:or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof;R2 is (OH), NH2, or NR&#39;R&#39;&#39; wherein R&#39; and R&#39;&#39; are independently lower alkyl (1-4C) or isand R1 is Asp-Ser-Gly-, R2 cannot be Asn-Val-Leu-Arg-Arg-Tyr.The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.